Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-3 (Cancelled)

Claim 4 **(Currently Amended):** A method for increasing neurotrophin levels in the ~~in the~~ central nervous system (CNS) of a patient with Parkinson's disease, amyotrophic lateral sclerosis, or stress-induced neurodegeneration, said method comprising administering to the patient an amount of a $GABA_B$ receptor antagonist sufficient to increase neurotrophin levels in the CNS of the patient.

Claims 5-16 (Cancelled)

Claim 17 (Previously presented): A method for increasing neurotrophin levels in the central nervous system (CNS) of a patient with Parkinson's disease, comprising administering to the patient an amount of a $GABA_B$ receptor antagonist sufficient to increase neurotrophin levels in the CNS of a patient with Parkinson's disease.

Claim 18 (**Currently amended**): A method for treating Parkinson's disease, comprising administering to a patient in need of such treatment a therapeutically effective amount of a $GABA_B$ receptor antagonist, thereby treating the patient.

Claim 19 (Previously presented): The method of claim 17 wherein the antagonist is administered daily.

Claim 20 (Previously presented): The method of claim 18 wherein the antagonist is administered daily.

Claim 21 (Previously presented): The method of claim 4 wherein the $GABA_B$ receptor antagonist is selected from the group consisting of 3-{1(S)-[3-(cyclohexylmethyl)hydroxyphosphinyl)-2(S)- hydroxy-propylamino]ethyl}benzoic acid; 3-{1(R)-[3-(cyclohexylmethyl)hydroxyphosphinyl-2(S)-hydroxy-propylamino]ethyl}benzoic acid; and 3-aminopropyl-(n-butyl)-phosphinic acid.

Claim 22 (Previously presented): The method of claim 17 wherein the $GABA_B$ receptor antagonist is selected from the group consisting of 3-{1(S)-[3-(cyclohexylmethyl)hydroxyphosphinyl)-2(S)- hydroxy-propylamino]ethyl}benzoic acid; 3-

{1(R)-[3-(cyclohexylmethyl)hydroxyphosphinyl-2(S)-hydroxy-propylamino]ethyl}benzoic acid; and 3-aminopropyl-(n-butyl)-phosphinic acid.

Claims 23 (Previously presented): The method of claim 18 wherein the $GABA_B$ receptor antagonist is selected from the group consisting of 3-{1(S)-[3-(cyclohexylmethyl)hydroxyphosphinyl)-2(S)- hydroxy-propylamino]ethyl}benzoic acid; 3-{1(R)-[3-(cyclohexylmethyl)hydroxyphosphinyl-2(S)-hydroxy-propylamino]ethyl}benzoic acid; and 3-aminopropyl-(n-butyl)-phosphinic acid.

Claim 24 (Previously presented): The method of Claim 4 where the $GABA_B$ receptor antagonist is administered to a patient with Parkinson's disease or amyotrophic lateral sclerosis.

Claim 25 **(Currently amended):** The method of Claim 24, ~~Claim 23~~ wherein the $GABA_B$ receptor antagonist is administered to a patient with Parkinson's disease.